Melodi Matrix™ in Breast Reconstruction

Last updated: December 19, 2024
Sponsor: Melodi Health, Inc.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Breast Reconstruction

Treatment

Absorbable Antibacterial Matrix

Clinical Study ID

NCT06027996
01-2023
  • Ages > 22
  • Female

Study Summary

Prospective, multicenter, randomized, controlled trial evaluating the safety and effectiveness of an absorbable antibacterial matrix device in two stage prepectoral alloplastic breast reconstruction.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Female.

  • Age 22 or older at the time of enrollment.

  • Is scheduled to undergo unilateral or bilateral mastectomy (including prophylactic)with immediate two-stage post-mastectomy alloplastic prepectoral breastreconstruction.

  • Is able to and willing to comply with the study requirements and providing informedconsent.

Exclusion

Exclusion Criteria:

  • Has prior history of neoadjuvant radiotherapy.

  • Has had prior history of failed tissue expansion or breast implantation at theintended reconstruction site.

  • Has an active abscess or infection requiring antibiotics anywhere in their bodywithin 30 days.

  • Has a Body Mass Index (BMI) < 14 or > 40.

  • Is pregnant or is nursing; or plans to become pregnant during the course of thestudy.

  • Has any connective tissue/autoimmune disorder or rheumatoid disease.

  • Has known allergies to study device materials.

  • Is participating in another interventional research study that may interfere withstudy endpoints.

  • Has limited life expectancy or co-morbid conditions, social/psychological problems,or cognitive impairments that precludes participation.

  • Has a medical condition or is taking medications that would result in elevated riskand/or affect the validity of the study.

  • Intraoperative assessment demonstrates unfavorable conditions (i.e., poor mastectomyskin flap thickness or viability) for immediate, two-stage post-mastectomyalloplastic prepectoral reconstruction in any breast.

Study Design

Total Participants: 702
Treatment Group(s): 1
Primary Treatment: Absorbable Antibacterial Matrix
Phase:
Study Start date:
August 09, 2024
Estimated Completion Date:
June 30, 2028

Connect with a study center

  • Stanford University

    Palo Alto, California 94304
    United States

    Active - Recruiting

  • Mayo Clinic

    Rochester, Minnesota 55905
    United States

    Active - Recruiting

  • The Ohio State University

    Columbus, Ohio 43212
    United States

    Active - Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina 29425
    United States

    Active - Recruiting

  • MD Anderson Cancer Center

    Houston, Texas 77030
    United States

    Active - Recruiting

  • University of Utah

    Salt Lake City, Utah 84112
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.